Randomized controlled trial· 2015

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Pi-Sunyer X, Astrup A, Fujioka K, et al.

New England Journal of Medicine

DOI
10.1056/nejmoa1411892
PubMed
26132939
Evidence level
high
Verification
verified

Summary

Randomized double-blind trial of liraglutide 3.0 mg or placebo, alongside diet and exercise, in adults with obesity or overweight and related comorbidity.

Limitations

The study assessed a selected trial population under structured support. Gastrointestinal adverse effects and discontinuation limit generalizability, and longer-term maintenance requires separate evidence.

Linked peptides

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.